Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-13

IS THERE ANY GSK INTEREST IN PETALION - hence lack of info re actual research which Starpharma is undertaking?

GSK’s Investment in Medicxi

In 2016, GSK became a founding investor in Medicxi Ventures 1 (MV1), a €210 million fund focused on early-stage life sciences investments in Europe. This fund was launched by Medicxi, which was established by the former life sciences team of Index Ventures. GSK’s involvement in MV1 was part of its commitment to the “asset-centric” investment model, aiming to support innovative biotech startups and accelerate drug discovery and development.

Additionally, GSK has invested in other Medicxi funds, including Medicxi Growth 1 (MG1), a $300 million late-stage life sciences fund. These investments are part of GSK’s strategy to collaborate with venture capital firms to access cutting-edge research and potential new therapies